395 related articles for article (PubMed ID: 10499637)
1. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
2. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G
Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
4. Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line.
Leonetti C; Biroccio A; Benassi B; Stringaro A; Stoppacciaro A; Semple SC; Zupi G
Cancer Gene Ther; 2001 Jun; 8(6):459-68. PubMed ID: 11498766
[TBL] [Abstract][Full Text] [Related]
5. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
[TBL] [Abstract][Full Text] [Related]
7. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells.
Ginobbi P; Geiser TA; Ombres D; Citro G
Anticancer Res; 1997; 17(1A):29-35. PubMed ID: 9066627
[TBL] [Abstract][Full Text] [Related]
8. Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression.
Stewart DA; Xu X; Thomas SD; Miller DM
Nucleic Acids Res; 2002 Jun; 30(11):2565-74. PubMed ID: 12034846
[TBL] [Abstract][Full Text] [Related]
9. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin.
Pastorino F; Mumbengegwi DR; Ribatti D; Ponzoni M; Allen TM
J Control Release; 2008 Feb; 126(1):85-94. PubMed ID: 18166243
[TBL] [Abstract][Full Text] [Related]
10. Enhancement effect of adenovirus-mediated antisense c-myc and caffeine on the cytotoxicity of cisplatin in osteosarcoma cell lines.
Xie XK; Yang DS; Ye ZM; Tao HM
Chemotherapy; 2009; 55(6):433-40. PubMed ID: 19996588
[TBL] [Abstract][Full Text] [Related]
11. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.
McClay EF; Jones JA; Winski PJ; Albright KD; Christen RD; Howell SB
Cancer Res; 1996 Sep; 56(17):3993-7. PubMed ID: 8752169
[TBL] [Abstract][Full Text] [Related]
12. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
Li M; Yu LL; Cai LQ; Wang HB; Wang ZH; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):121-5. PubMed ID: 16640863
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibition of SK-MEL-30 human melanoma cells by antisense c-myc oligonucleotides delivered by poly(N-isopropylacrylamide)/ poly(ethyleneimine) copolymer.
Dinçer S; Oskay EK; Piskin AK; Zeybek ND; Pişkin E
J Tissue Eng Regen Med; 2010 Jun; 4(4):284-90. PubMed ID: 19967748
[TBL] [Abstract][Full Text] [Related]
14. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells.
Biliran H; Banerjee S; Thakur A; Sarkar FH; Bollig A; Ahmed F; Wu J; Sun Y; Liao JD
Clin Cancer Res; 2007 May; 13(9):2811-21. PubMed ID: 17473215
[TBL] [Abstract][Full Text] [Related]
15. [Expression and reversion of drug resistance- and apoptosis-related genes of a DDP-resistant lung adenocarcinoma cell line A549DDP].
Wang J; Liu X; Wu M
Zhonghua Zhong Liu Za Zhi; 1999 Nov; 21(6):422-6. PubMed ID: 11776616
[TBL] [Abstract][Full Text] [Related]
16. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
[TBL] [Abstract][Full Text] [Related]
17. Recombinant antisense C-myc adenovirus increase in vitro sensitivity of osteosarcoma MG-63 cells to cisplatin.
Xie XK; Yang DS; Ye ZM; Tao HM
Cancer Invest; 2006 Feb; 24(1):1-8. PubMed ID: 16466985
[TBL] [Abstract][Full Text] [Related]
18. c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model.
Sekhon HS; London CA; Sekhon M; Iversen PL; Devi GR
Lung Cancer; 2008 Jun; 60(3):347-54. PubMed ID: 18096271
[TBL] [Abstract][Full Text] [Related]
19. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
Miyake H; Hara I; Kamidono S; Gleave ME
Clin Cancer Res; 2001 Dec; 7(12):4245-52. PubMed ID: 11751526
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]